Journey Medical (NASDAQ:DERM) shares are trading higher Monday after the company announced the U.S. Food and Drug Administration approved its Emrosi drug for the treatment of rosacea. The Dow ...

March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S ...

Journey Medical (DERM) delivered earnings and revenue surprises of 136.36% and 1.84%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Journey Medical Corporation, a pharmaceutical company focused on marketing FDA-approved dermatological treatments, announced it will release its year-end 2024 financial results on March 26 ...

FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled TotalRevenues for the Full Year ...

Journey Medical Corporation has announced the launch and initial distribution of Emrosi™, a new prescription medication designed to treat inflammatory lesions of rosacea in adults. Emrosi ...

Follow the intellectual and emotional journey of a group of medical students at Captured through verit scenes and personal video diaries, the film offers an inside look at Americas healthcare system ...

Journey Medical Co. (NASDAQ:DERM – Free Report) – Roth Capital raised their Q3 2025 earnings per share (EPS) estimates for shares of Journey Medical in a research note issued on Thursday ...